HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

10.870

-0.160-1.45%

Volume:949.00K

Turnover:10.26M

Market Cap:4.13B

PE:-9.48

High:11.100

Open:10.900

Low:10.700

Close:11.030

52wk High:41.400

52wk Low:9.850

Shares:380.07M

HK Float Shares:375.46M

Volume Ratio:0.68

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.146

ROE:--

ROA:-27.71%

PB:10.18

PE(LYR):-9.48

PS:33954.24

Loading ...

Overview Company News Filings

TYK MEDICINES-B Shares Surge Over 5% Following H-Share Reform Completion and New Drug Application Milestone

TYK MEDICINES-B (02410) Releases Monthly Return for February 2026

Bulletin Express

TYK MEDICINES-B (02410) Announces Completion of H Share Full Circulation

Bulletin Express

TYK MEDICINES-B (Stock Code: 02410) Announces Conversion of 4.61 Million Unlisted Shares to H Shares

Bulletin Express

TYK MEDICINES-B Completes H-Share Full Circulation Process

TYK Medicines Completes H-Share Full Circulation, Converted Shares to Start Trading March 5

TYK MEDICINES-B Announces RMB 83.5 Million Capital Injection into Subsidiary

Tyk Medicines Inc - Co, Others Agreed to Increase the Registered Capital of Tyk Bio by RMB6.49 Million

THOMSON REUTERS

Tyk Medicines Inc - Co's Stake in Tyk Bio Reduced to 39.03%

THOMSON REUTERS

TYK Medicines’ stake in TYK Bio falls to 39% after RMB83.5 million capital raise

TYK Medicines Gets Regulatory Nod to List 4.6 Million Converted Shares on Hong Kong Bourse

MT Newswires Live

TYK Medicines (2410) Receives Approval for 4.61 Million H-Share Conversion

Bulletin Express

TYK MEDICINES-B Receives Stock Exchange Approval for H-Share Full Circulation Plan

TYK Medicines' Application for Lung Cancer Drug Accepted in China

MT Newswires Live

TYK Medicines, Inc. (2410) Announces NDA Acceptance for Asandeutertinib (TY-9591)

Bulletin Express

TYK MEDICINES-B's New Drug Application for TY-9591 Tablets Accepted by Regulatory Authority

Tyk Medicines Inc - Announces Nda Acceptance for Asandeutertinib

THOMSON REUTERS

TYK Medicines NDA for Asandeutertinib Accepted by China’s NMPA

TYK MEDICINES-B Shares Surge Nearly 5% in Afternoon Session as Key Drug Gains Priority Review Status

TYK Medicines (02410) Announces Monthly Securities Movements for January 2026

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02410/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02410","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"TYK MEDICINES-B","latestPrice":10.87,"timestamp":1773293147824,"preClose":11.03,"halted":0,"volume":949000,"delay":0,"changeRate":-0.014505893019038998,"floatShares":375457818,"shares":380065818,"eps":-1.146139,"marketStatus":"Trading","change":-0.16,"latestTime":"03-12 13:26:08","open":10.9,"high":11.1,"low":10.7,"amount":10263685,"amplitude":0.036265,"askPrice":10.87,"askSize":2500,"bidPrice":10.84,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.845803,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1773303000000},"marketStatusCode":2,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":11.03,"openAndCloseTimeList":[[1773279000000,1773288000000],[1773291600000,1773302400000]],"volumeRatio":0.681425,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02410\",,,,,undefined,":{"symbol":"02410","floatShares":375457818,"roa":"-27.71%","roe":"--","lyrEps":-1.146139,"volumeRatio":0.681425,"shares":380065818,"dividePrice":0,"high":11.1,"amplitude":0.036265,"preClose":11.03,"low":10.7,"week52Low":9.85,"pbRate":"10.18","psRate":"33954.24","week52High":41.4,"institutionHeld":0,"latestPrice":10.87,"committee":-0.666667,"eps":-1.146139,"divideRate":0,"volume":949000,"delay":0,"ttmEps":-0.845803,"open":10.9,"prevYearClose":13.11,"prevWeekClose":11.1,"prevMonthClose":12.6,"prevQuarterClose":13.11,"fiveDayClose":10.77,"twentyDayClose":12.86,"sixtyDayClose":13.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02410\",params:#limit:5,,,undefined,":[{"date":"2025-08-31","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756603800000,"name":null,"time":"","dateTimestamp":1756569600000,"actualEps":null},{"date":"2025-03-27","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743039000000,"name":null,"time":"","dateTimestamp":1743004800000,"actualEps":null},{"date":"2024-08-30","symbol":"02410","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724981400000,"name":null,"time":"","dateTimestamp":1724947200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02410\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02410\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1747411200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02410\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02410","date":"2026-03-11","current":-12.8044,"percent":0.971279,"low":-45.171338,"twenty":-24.765114,"median":-18.687981,"eighty":-15.856653,"high":-10.104382,"avg":-20.547594,"sd":6.156729,"marketCap":4192125972},"quantilePoints":[{"date":"2024-08-23","current":-18.036629,"twenty":-16.647141,"median":-14.72623,"eighty":-12.008468,"marketCap":8010053668},{"date":"2024-08-30","current":-17.916348,"twenty":-18.108709,"median":-17.490261,"eighty":-14.277882,"marketCap":8010053668},{"date":"2024-09-06","current":-22.38992,"twenty":-20.387629,"median":-17.957821,"eighty":-15.985061,"marketCap":10531737231},{"date":"2024-09-13","current":-25.215246,"twenty":-24.52304,"median":-18.767123,"eighty":-16.911292,"marketCap":11829662594},{"date":"2024-09-20","current":-22.432724,"twenty":-24.518581,"median":-20.496807,"eighty":-17.208183,"marketCap":10587362603},{"date":"2024-09-27","current":-24.719835,"twenty":-24.497927,"median":-22.38992,"eighty":-17.671485,"marketCap":11736953639},{"date":"2024-10-04","current":-24.95032,"twenty":-24.87878,"median":-23.321155,"eighty":-17.932937,"marketCap":11792579012},{"date":"2024-10-10","current":-25.38933,"twenty":-24.941363,"median":-23.362473,"eighty":-17.973583,"marketCap":11922371548},{"date":"2024-10-18","current":-26.355956,"twenty":-25.311733,"median":-23.798709,"eighty":-18.108709,"marketCap":12311749157},{"date":"2024-10-25","current":-24.571342,"twenty":-25.374683,"median":-24.122054,"eighty":-18.545067,"marketCap":11477368567},{"date":"2024-11-01","current":-18.445843,"twenty":-25.311733,"median":-23.998666,"eighty":-18.584118,"marketCap":8621932768},{"date":"2024-11-08","current":-20.323115,"twenty":-25.278482,"median":-23.623818,"eighty":-17.973583,"marketCap":9456313359},{"date":"2024-11-15","current":-19.45318,"twenty":-25.171449,"median":-23.425489,"eighty":-18.108709,"marketCap":8955685004},{"date":"2024-11-22","current":-24.620137,"twenty":-24.988066,"median":-23.362473,"eighty":-18.406793,"marketCap":11329034239},{"date":"2024-11-29","current":-31.047836,"twenty":-25.311733,"median":-23.554037,"eighty":-18.584118,"marketCap":14277178993},{"date":"2024-12-06","current":-34.758675,"twenty":-25.786797,"median":-23.737743,"eighty":-19.168188,"marketCap":15945940174},{"date":"2024-12-13","current":-35.961329,"twenty":-26.0415,"median":-24.070769,"eighty":-19.324298,"marketCap":16465110319},{"date":"2024-12-20","current":-44.500897,"twenty":-30.298107,"median":-24.44033,"eighty":-19.494791,"marketCap":20284719244},{"date":"2024-12-27","current":-43.273475,"twenty":-31.455257,"median":-24.553474,"eighty":-19.619623,"marketCap":19709923726},{"date":"2025-01-03","current":-39.042242,"twenty":-33.760908,"median":-24.669986,"eighty":-19.709581,"marketCap":17800119264},{"date":"2025-01-10","current":-16.73771,"twenty":-34.083555,"median":-24.719835,"eighty":-19.709581,"marketCap":7602134269},{"date":"2025-01-17","current":-16.071561,"twenty":-33.760908,"median":-24.553474,"eighty":-18.860667,"marketCap":7305465614},{"date":"2025-01-24","current":-20.268382,"twenty":-32.413923,"median":-24.349989,"eighty":-19.230133,"marketCap":9270895450},{"date":"2025-01-28","current":-18.549699,"twenty":-31.591026,"median":-24.122054,"eighty":-18.549699,"marketCap":8529223814},{"date":"2025-02-07","current":-17.965815,"twenty":-31.472067,"median":-23.871541,"eighty":-18.275892,"marketCap":8214013368},{"date":"2025-02-14","current":-19.878813,"twenty":-31.451054,"median":-23.623818,"eighty":-18.275892,"marketCap":9066935750},{"date":"2025-02-21","current":-25.066745,"twenty":-31.047836,"median":-23.789321,"eighty":-18.32609,"marketCap":11495910358},{"date":"2025-02-28","current":-26.244856,"twenty":-30.411824,"median":-23.765234,"eighty":-18.39703,"marketCap":11996538712},{"date":"2025-03-07","current":-24.725844,"twenty":-30.135297,"median":-23.927628,"eighty":-18.445843,"marketCap":11347576030},{"date":"2025-03-14","current":-23.101371,"twenty":-29.84324,"median":-23.977848,"eighty":-18.549699,"marketCap":10605904394},{"date":"2025-03-21","current":-22.868028,"twenty":-28.789228,"median":-23.789321,"eighty":-18.691799,"marketCap":10494653649},{"date":"2025-03-28","current":-28.703724,"twenty":-28.703724,"median":-23.977848,"eighty":-19.110968,"marketCap":13146129748},{"date":"2025-04-03","current":-29.204856,"twenty":-29.744706,"median":-24.122054,"eighty":-19.131966,"marketCap":12070705875},{"date":"2025-04-11","current":-24.387234,"twenty":-29.307899,"median":-24.067881,"eighty":-19.145106,"marketCap":10012567086},{"date":"2025-04-17","current":-24.599189,"twenty":-28.955479,"median":-24.067881,"eighty":-19.224594,"marketCap":10123817831},{"date":"2025-04-25","current":-24.758022,"twenty":-28.755026,"median":-24.236021,"eighty":-19.282593,"marketCap":10197984995},{"date":"2025-05-02","current":-30.859428,"twenty":-28.772127,"median":-24.368612,"eighty":-19.308976,"marketCap":12738210348},{"date":"2025-05-09","current":-26.222368,"twenty":-28.789228,"median":-24.487968,"eighty":-19.376573,"marketCap":11477368567},{"date":"2025-05-16","current":-19.875071,"twenty":-28.703724,"median":-24.44033,"eighty":-19.45318,"marketCap":8770267095},{"date":"2025-05-23","current":-18.391406,"twenty":-28.460584,"median":-24.320388,"eighty":-19.147078,"marketCap":8139846205},{"date":"2025-05-30","current":-16.767615,"twenty":-28.328721,"median":-24.116277,"eighty":-18.777931,"marketCap":7453799941},{"date":"2025-06-06","current":-19.720458,"twenty":-27.077703,"median":-23.93026,"eighty":-18.847277,"marketCap":8788808886},{"date":"2025-06-13","current":-16.18601,"twenty":-26.697665,"median":-23.850097,"eighty":-18.709822,"marketCap":7216465018},{"date":"2025-06-20","current":-14.05098,"twenty":-26.664525,"median":-23.778892,"eighty":-18.426653,"marketCap":6252291891},{"date":"2025-06-27","current":-16.3221,"twenty":-26.630078,"median":-23.66211,"eighty":-18.32609,"marketCap":7283215465},{"date":"2025-07-04","current":-17.493079,"twenty":-26.41078,"median":-23.623818,"eighty":-18.194509,"marketCap":7806093968},{"date":"2025-07-11","current":-16.487526,"twenty":-26.267076,"median":-23.430941,"eighty":-17.964216,"marketCap":7349965912},{"date":"2025-07-18","current":-15.867745,"twenty":-26.226866,"median":-23.321155,"eighty":-17.866761,"marketCap":7068130691},{"date":"2025-07-25","current":-16.407488,"twenty":-26.143659,"median":-23.070409,"eighty":-17.335488,"marketCap":7335132480},{"date":"2025-08-01","current":-14.539711,"twenty":-26.072617,"median":-22.868028,"eighty":-17.325642,"marketCap":6459959949},{"date":"2025-08-08","current":-15.316665,"twenty":-25.987382,"median":-22.563641,"eighty":-17.04089,"marketCap":6822181433},{"date":"2025-08-15","current":-17.450454,"twenty":-25.968574,"median":-22.406203,"eighty":-16.915178,"marketCap":7760944003},{"date":"2025-08-22","current":-13.484776,"twenty":-25.95357,"median":-22.354126,"eighty":-16.718364,"marketCap":5978435317},{"date":"2025-08-29","current":-12.516323,"twenty":-25.925655,"median":-21.46252,"eighty":-16.486483,"marketCap":5575565550},{"date":"2025-09-05","current":-19.23268,"twenty":-25.919389,"median":-21.226743,"eighty":-16.486483,"marketCap":5883418862},{"date":"2025-09-12","current":-18.156363,"twenty":-25.850806,"median":-20.678772,"eighty":-16.541494,"marketCap":5564163575},{"date":"2025-09-19","current":-18.839434,"twenty":-25.807696,"median":-20.500943,"eighty":-16.56352,"marketCap":5769399117},{"date":"2025-09-26","current":-19.348832,"twenty":-25.743581,"median":-20.268382,"eighty":-16.654406,"marketCap":5910023469},{"date":"2025-10-03","current":-22.468168,"twenty":-25.650075,"median":-20.314843,"eighty":-16.707921,"marketCap":6879191305},{"date":"2025-10-10","current":-19.927643,"twenty":-25.596841,"median":-20.323115,"eighty":-16.732368,"marketCap":6092455062},{"date":"2025-10-17","current":-19.134493,"twenty":-25.519561,"median":-20.155539,"eighty":-16.749672,"marketCap":5845412280},{"date":"2025-10-24","current":-17.635142,"twenty":-25.404318,"median":-19.980008,"eighty":-16.781291,"marketCap":5389333299},{"date":"2025-10-31","current":-19.024541,"twenty":-25.400784,"median":-19.927643,"eighty":-16.830147,"marketCap":5822608331},{"date":"2025-11-07","current":-17.694439,"twenty":-25.37593,"median":-19.869193,"eighty":-16.945559,"marketCap":5412137248},{"date":"2025-11-14","current":-17.099248,"twenty":-25.321084,"median":-19.741813,"eighty":-16.951188,"marketCap":5244908288},{"date":"2025-11-21","current":-15.19815,"twenty":-25.311733,"median":-19.694587,"eighty":-16.919035,"marketCap":4659606928},{"date":"2025-11-28","current":-16.711808,"twenty":-25.293455,"median":-19.641679,"eighty":-16.730587,"marketCap":5142290517},{"date":"2025-12-05","current":-17.262657,"twenty":-25.275139,"median":-19.635782,"eighty":-16.587841,"marketCap":5320921452},{"date":"2025-12-12","current":-16.160016,"twenty":-25.213434,"median":-19.544821,"eighty":-16.497144,"marketCap":4990264190},{"date":"2025-12-19","current":-16.355316,"twenty":-25.19336,"median":-19.414876,"eighty":-16.454475,"marketCap":5062476695},{"date":"2025-12-24","current":-15.692499,"twenty":-25.154877,"median":-19.348832,"eighty":-16.406101,"marketCap":4872443786},{"date":"2026-01-02","current":-15.765099,"twenty":-25.10227,"median":-19.292077,"eighty":-16.35327,"marketCap":4914251026},{"date":"2026-01-09","current":-17.392186,"twenty":-25.070347,"median":-19.235279,"eighty":-16.345574,"marketCap":5434941197},{"date":"2026-01-16","current":-16.438751,"twenty":-25.06473,"median":-19.137216,"eighty":-16.35327,"marketCap":5153692492},{"date":"2026-01-23","current":-15.75073,"twenty":-25.023112,"median":-19.120814,"eighty":-16.314941,"marketCap":4933254317},{"date":"2026-01-30","current":-15.280433,"twenty":-24.971672,"median":-19.022068,"eighty":-16.22453,"marketCap":4807832597},{"date":"2026-02-06","current":-15.542994,"twenty":-24.952303,"median":-18.937078,"eighty":-16.152588,"marketCap":4902849052},{"date":"2026-02-13","current":-15.334427,"twenty":-24.923448,"median":-18.860882,"eighty":-16.099082,"marketCap":4864842470},{"date":"2026-02-20","current":-15.572498,"twenty":-24.905533,"median":-18.847277,"eighty":-16.071561,"marketCap":4933254317},{"date":"2026-02-27","current":-14.952615,"twenty":-24.827654,"median":-18.801141,"eighty":-15.988536,"marketCap":4788829306},{"date":"2026-03-06","current":-13.279596,"twenty":-24.77147,"median":-18.709822,"eighty":-15.892604,"marketCap":4218730579},{"date":"2026-03-11","current":-13.134921,"twenty":-24.765114,"median":-18.687981,"eighty":-15.856653,"marketCap":4192125972}],"updateTime":1773288190966},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02410\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1133725281","title":"TYK MEDICINES-B Shares Surge Over 5% Following H-Share Reform Completion and New Drug Application Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1133725281","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133725281?lang=en_us&edition=fundamental","pubTime":"2026-03-06 12:01","pubTimestamp":1772769706,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) rose more than 5%, with a gain of 4.92% at the time of writing to HK$11.34, generating a turnover of HK$27.5877 million. On March 4, the company announced that the conversion...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VT","BK1574","VXUS","09939","02410","BK1161","BK1515","159938","BK4588"],"gpt_icon":0},{"id":"1165073169","title":"TYK MEDICINES-B (02410) Releases Monthly Return for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1165073169","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165073169?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:17","pubTimestamp":1772615856,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) released its Monthly Return on Movements in Securities for the period ended 28 February 2026. According to the announcement, the registered H shares remained at 375,457,818,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1110993136","title":"TYK MEDICINES-B (02410) Announces Completion of H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1110993136","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110993136?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:17","pubTimestamp":1772615837,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) announced the completion of its H share full circulation process on March 4, 2026. According to the announcement, 4.61 million unlisted shares were successfully converted into...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1102975301","title":"TYK MEDICINES-B (Stock Code: 02410) Announces Conversion of 4.61 Million Unlisted Shares to H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1102975301","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102975301?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:15","pubTimestamp":1772615739,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (Stock Code: 02410) disclosed that as of 28 February 2026, the company had approximately 375.46 million H shares. On 4 March 2026, 4.61 million unlisted shares were converted into H...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1138822014","title":"TYK MEDICINES-B Completes H-Share Full Circulation Process","url":"https://stock-news.laohu8.com/highlight/detail?id=1138822014","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138822014?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:48","pubTimestamp":1772614108,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that the conversion of 4.608 million non-tradable shares into H-shares was successfully completed on March 4, 2026. These newly converted H-shares are scheduled to commence trading on the Hong Kong Stock Exchange at 9:00 a.m. on March 5, 2026.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1515","09939","BK1574","159938","BK1161"],"gpt_icon":0},{"id":"2616580116","title":"TYK Medicines Completes H-Share Full Circulation, Converted Shares to Start Trading March 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580116","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616580116?lang=en_us&edition=fundamental","pubTime":"2026-03-04 16:38","pubTimestamp":1772613504,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. has completed its H-share full circulation, converting 4,608,000 previously unlisted shares into H shares on March 4, 2026. Trading of the converted H shares is set to begin on the Hong Kong Stock Exchange at 9:00 a.m. on March 5, 2026, bringing the company’s total listed H shares to 380,065,818.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL7WBgf4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410"],"gpt_icon":0},{"id":"1193005236","title":"TYK MEDICINES-B Announces RMB 83.5 Million Capital Injection into Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=1193005236","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193005236?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:10","pubTimestamp":1772194221,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has disclosed that on February 27, 2026, after trading hours, existing shareholders, including the company, along with TYK Bio and subscribers, entered into a capital increase...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","BK1161","02410","159938","09939"],"gpt_icon":0},{"id":"2614453830","title":"Tyk Medicines Inc - Co, Others Agreed to Increase the Registered Capital of Tyk Bio by RMB6.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614453830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614453830?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:55","pubTimestamp":1772193313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN1BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2614304348","title":"Tyk Medicines Inc - Co's Stake in Tyk Bio Reduced to 39.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614304348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614304348?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:55","pubTimestamp":1772193313,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN1BG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2614183014","title":"TYK Medicines’ stake in TYK Bio falls to 39% after RMB83.5 million capital raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2614183014","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614183014?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:54","pubTimestamp":1772193295,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. agreed to dilute its stake in TYK Biotechnology Co., Ltd. through a roughly RMB83.5 million capital increase by new investors, raising TYK Bio’s registered capital from RMB14.0 million to about RMB20.49 million. After completion, TYK Medicines’ ownership in TYK Bio will fall to about 39.03% from 57.14%, and TYK Bio will no longer be consolidated as a subsidiary. TYK Medicines said it expects to record an estimated gain of about RMB100 million from the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 27, 2026, and is solely respon","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL8jJ1FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"gpt_icon":0},{"id":"2610941557","title":"TYK Medicines Gets Regulatory Nod to List 4.6 Million Converted Shares on Hong Kong Bourse","url":"https://stock-news.laohu8.com/highlight/detail?id=2610941557","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610941557?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:00","pubTimestamp":1770890436,"startTime":"0","endTime":"0","summary":"TYK Medicines  obtained approval from the Listing Committee of the Hong Kong Stock Exchange to list over 4.6 million shares to be converted under the firm's Hong Kong-listed share full circulation.The shares, held by one shareholder, represent 1.21% of the pharmaceutical company's issued share capital, according to a Thursday Hong Kong bourse filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","02410","BK1161"],"gpt_icon":0},{"id":"1163699431","title":"TYK Medicines (2410) Receives Approval for 4.61 Million H-Share Conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=1163699431","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163699431?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:25","pubTimestamp":1770888355,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (浙江同源康醫藥股份有限公司, stock code: 2410) obtained listing approval from The Stock Exchange of Hong Kong Limited on February 11, 2026, for the conversion of 4.61 million unlisted shares...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1152510017","title":"TYK MEDICINES-B Receives Stock Exchange Approval for H-Share Full Circulation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1152510017","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152510017?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:08","pubTimestamp":1770887296,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that the company applied to the Stock Exchange's listing committee for approval to list and trade 4.608 million H-shares. These shares were converted from 4.608...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02410","09939","159938","BK1574","BK1515"],"gpt_icon":0},{"id":"2609569027","title":"TYK Medicines' Application for Lung Cancer Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609569027?lang=en_us&edition=fundamental","pubTime":"2026-02-06 18:00","pubTimestamp":1770372036,"startTime":"0","endTime":"0","summary":"TYK Medicines'  new drug application for Asandeutertinib was accepted by China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The acceptance is for the indication of first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MDCO","BK1161","02410"],"gpt_icon":0},{"id":"1170178089","title":"TYK Medicines, Inc. (2410) Announces NDA Acceptance for Asandeutertinib (TY-9591)","url":"https://stock-news.laohu8.com/highlight/detail?id=1170178089","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170178089?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:22","pubTimestamp":1770369748,"startTime":"0","endTime":"0","summary":"TYK Medicines, Inc. (Stock Code: 2410) announced that the National Medical Products Administration’s Center for Drug Evaluation has accepted its New Drug Application for Asandeutertinib (TY-9591)....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0},{"id":"1168835529","title":"TYK MEDICINES-B's New Drug Application for TY-9591 Tablets Accepted by Regulatory Authority","url":"https://stock-news.laohu8.com/highlight/detail?id=1168835529","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168835529?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:06","pubTimestamp":1770368786,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) has announced that the New Drug Application (NDA) for its investigational Class 1 new drug, TY-9591 tablets (Edotinib Mesylate Tablets), has been accepted for review by the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02410","BK1515","09939","159938","TY"],"gpt_icon":0},{"id":"2609565121","title":"Tyk Medicines Inc - Announces Nda Acceptance for Asandeutertinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2609565121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609565121?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:00","pubTimestamp":1770368453,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z201R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02410"],"gpt_icon":0},{"id":"2609406565","title":"TYK Medicines NDA for Asandeutertinib Accepted by China’s NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2609406565","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609406565?lang=en_us&edition=fundamental","pubTime":"2026-02-06 17:00","pubTimestamp":1770368447,"startTime":"0","endTime":"0","summary":"TYK Medicines Inc. announced that its New Drug Application  for Asandeutertinib  has been accepted by the Center for Drug Evaluation of the National Medical Products Administration  in China. The application is for the registration of Asandeutertinib as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer  harboring EGFR exon 19 deletion or exon 21  substitution mutations, including those with central nervous system metastases. The acceptance follows a review under Article 32 of the Administrative License Law of the People’s Republic of China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL7MQWqB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","BK1161"],"gpt_icon":0},{"id":"1102746798","title":"TYK MEDICINES-B Shares Surge Nearly 5% in Afternoon Session as Key Drug Gains Priority Review Status","url":"https://stock-news.laohu8.com/highlight/detail?id=1102746798","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102746798?lang=en_us&edition=fundamental","pubTime":"2026-02-06 14:26","pubTimestamp":1770359177,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) experienced a notable increase of nearly 5% during afternoon trading. At the time of writing, the stock was up 3.65%, trading at HK$13.06, with a turnover of HK$28.91 million....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4585","09939","159938","BK1161","BK4588","02410","BK1574","VT","BK1515"],"gpt_icon":0},{"id":"1144504941","title":"TYK Medicines (02410) Announces Monthly Securities Movements for January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1144504941","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144504941?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:45","pubTimestamp":1770111912,"startTime":"0","endTime":"0","summary":"TYK Medicines (02410) submitted its Monthly Return for the period ended January 31, 2026, reporting no changes in the registered share capital. The total authorized/registered share capital remained...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":63,"code":"91000000","status":"200"}]}}